MedTrace Logo

Thrombosomes® in Bleeding Thrombocytopenic Patients

NCT03394755 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-04-14

Study results available
· View outcomes & findings →

Summary

The study evaluates the safety and potential early signals of efficacy of allogeneic Thrombosomes in bleeding thrombocytopenic patients

Conditions

Interventions

BIOLOGICAL

Thrombosomes

Freeze-dried platelets

Sponsors & Collaborators

Principal Investigators

  • Michael Fitzpatrick · Cellphire Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-19
Primary Completion
2019-08-01
Completion
2019-09-25
FDA Drug
Yes

Countries

  • United States
  • Norway

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03394755 on ClinicalTrials.gov